HOME >> BIOLOGY >> NEWS
Hepatitis C complicated by morphine withdrawal

Philadelphia, PAResearchers at the University of Pennsylvania have demonstrated that morphine withdrawal complicates hepatitis C by suppressing IFN-alpha-mediated immunity and enhancing virus replication. The paper by Wang et al., Morphine withdrawal enhances hepatitis C virus (HCV) replicon expression, appears in the November issue of The American Journal of Pathology and is accompanied by a commentary.

Hepatitis C virus (HCV) is common among intravenous drug users, with 70 to 80% of abusers infected in the United States. This high association has peaked interest in determining the effects of drug abuse, specifically opiates, on progression of the disease. The discovery of such an association would impact treatment of both HCV infection and drug abuse.

Dr. Wen-Zhe Ho has been interested in such interplay for some time. His laboratory has previously shown using cell culture that morphine enhances virus replication and inhibits IFN-alpha (a natural anti-viral factor produced by immune, as well as host cells, and the only one approved in recombinant form for treating HCV infection). To further these results, his lab has used a cell model system to determine the consequences of morphine withdrawal, which is a common recurring event in opioid users.

Chuan-Qing Wang and colleagues examined the effects of morphine withdrawal (MW) on HCV-infected cultured liver cells by exposing cells to the drug for four days followed by its removal. They also assessed the effects of using naloxone, to block the opioid receptors, in conjunction with drug removal, i.e. precipitated morphine withdrawal (PW). To measure HCV replication, they used a virus-like replicon that mimics the events that occur in liver cells and expression of viral RNA and proteins that HCV uses. Although the replicon does not produce the infectious virus, the HCV replicon system represents the best available system for examining the impact of opiates on HCV at the time of their r
'"/>

Contact: Audra E. Cox
acox@asip.org
301-634-7409
American Journal of Pathology
28-Oct-2005


Page: 1 2

Related biology news :

1. Hepatitis C helicase unwinds DNA in a spring-loaded, 3-step process
2. Hepatitis B drug can compromise HIV treatment
3. Hepatitis E takes a piggyback
4. New hope for Hepatitis C research
5. Hepatitis C therapy: Inhibiting newly discovered microDNA molecule
6. New insights into protein synthesis and Hepatitis C infections
7. Hepatitis B accounts for 40 percent of missing Asian women
8. Identification of a protein important for Hepatitis B replication
9. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
10. Hepatitis C virus linked to non-Hodgkins lymphoma
11. Efficacy of once-daily Avelox for complicated abdominal infections highlighted at ICAAC

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/11/2018)... Md. (PRWEB) , ... October 11, 2018 , ... ... economy is the vision behind the National Institute for Innovation in Manufacturing Biopharmaceuticals ... array of projects designed to advance biopharmaceutical manufacturing and workforce development in the ...
(Date:10/5/2018)... ... October 04, 2018 , ... ... communications and collaboration solutions, was present at Microsoft Ignite 2018, in Orlando, Florida, ... solutions. , Microsoft issued a statement about the new direction of Skype for ...
(Date:10/5/2018)... PRINCETON, N.J. (PRWEB) , ... October 04, 2018 , ... ... will be exhibiting at the CDISC U.S. Interchange in Bethesda, MD on October 8-12, ... (BBSW), in Foster City, CA on November 5-6, 2018. , CDISC Interchanges are ...
Breaking Biology News(10 mins):
(Date:9/28/2018)... ... September 28, 2018 , ... GlycoMark®, Inc. has ... of the GlycoMark test, the only FDA-cleared blood test specific to detecting recent ... promote and offer the GlycoMark test to its network of physicians through its ...
(Date:9/27/2018)... ... September 26, 2018 , ... NDA ... Cimler, a senior quality, regulatory, and in vitro diagnostic device expert with more ... industry has joined the firm as an Expert Consultant. Her experience includes leadership ...
(Date:9/27/2018)... ... September 26, 2018 , ... Medable was named DPharm ... build the first human digitome, a digital representation of human health and disease, ... integration of all data sources. Dr. Michelle Longmire, Co-Founder and CEO of Medable, ...
(Date:9/27/2018)... ... September 27, 2018 , ... This past weekend ... SureAdhere Mobile Technology, Inc. announced they will formally merge companies and integrate their ... tuberculosis (TB) and other diseases. These two social enterprise corporations, both of which ...
Breaking Biology Technology:
Cached News: